Advertisement

Is the Basis of Cleaning Autologous Bone Marrow Transplants in Leukemia Strong Enough?

  • B. Löwenberg
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

Bone marrow transplantation (BMT) from allogeneic donors following intensive chemotherapy and total body irradiation produces lasting remissions in a significant number of patients with acute lymphoblastic and myeloblastic leukemia (1–4). Autologous bone marrow transplantation (ABMT) in patients with acute leukemia may benefit from the same cytotoxic therapy. Its attractivity relates to the fact that each patient would have a donor, i.e. be his or her own donor, and that (in the absence of graft-versus-host disease) age restriction for transplantation is far less to be considered. On the other hand, ABMT is likely to involve a higher rate of leukemia relapse post transplantation. The first results of ABMT were obtained in end stage patients, and although they resulted in new remissions, these were usually of short duration (5). More recently several groups have started ABMT in patients with acute leukemia during their complete remission. This approach is foreseen to achieve a tumor cell killing due to: a) the pretransplant chemo- and radiotherapy; b) autologous bone marrow is probably contaminated with subclinical numbers of leukemic cells; the reinfusion of autologous bone marrow may result in a further decrease of tumor due to loss of cells in various tissues following intravenous administration (inappropriate seeding) (6–9); c) when purging methods are applied to the marrow graft, neoplastic cells may be successfully eliminated.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute non lymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Blume KG, Beutler E, Bross KJ, et al. Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980; 302: 1041–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Powles RL, Clink HM, Bandini G, et al. The place of bone marrow transplantation in acute myelogenous leukemia. Lancet 1980;i:1047–50.CrossRefGoogle Scholar
  4. 4.
    Thomas ED, Clift RA, Buckner CD. Marrow transplantation for patients with acute non lymphoblastic leukemia who achieve a first remission. Cancer Treat Rep 1982; 66: 1463–6.PubMedGoogle Scholar
  5. 5.
    Dicke KA, Spitzer G, Peters L, et al. Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet 1979;i:514–7.CrossRefGoogle Scholar
  6. 6.
    Ishidate M, Aoshima M, Sakurai Y. Population changes of a rat leukemia by different sorts of transplantation. J Natl Cancer Inst 1974; 53: 773–9.PubMedGoogle Scholar
  7. 7.
    Hagenbeek A. Introduction of BN myelocytic leukemia. Leuk Res 1977; 1: 85–90.CrossRefGoogle Scholar
  8. 8.
    Harris EB, Hoezler D. Proliferation kinetics of the L5222 leukemia in vivo. Leuk Res 1977; 1: 93–5.CrossRefGoogle Scholar
  9. 9.
    Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anti-cancer agents. XIII. On the criteria and kinetics associated with ‘curability’ of experimental leukemia. Cancer Chemother Rept 1964; 35: 1–111.Google Scholar
  10. 10.
    Touw IP, Löwenberg B. Differentiation of human acute myeloid leukemias following colony formation in vitro detected with monoclonal antibodies. Blood 1984 (submitted).Google Scholar
  11. 11.
    Wouters R, Löwenberg B. On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes. Blood 1984; 63: 684–9.PubMedGoogle Scholar
  12. 12.
    Tax WJM, Willems HW, Kibbelaar MBA, et al. Monoclonal antibodies against human thymocytes and T lymphocytes. In: Peeters H, ed. Protides of the biological fluids. Oxford: Pergamonn Press 29th Colloquium, 1981: 701–4.Google Scholar
  13. 13.
    Van der Reyden HJ, Van Rhenen DJ, Lansdorp PM, et al. A comparison of surface marker analysis and FAB classification in acute myeloid leukemia. Blood 1983; 61: 433–8.Google Scholar
  14. 14.
    Ferrero D, Pessano S, Pagliardi GL, Rovera G. Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. Blood 1983; 61: 171–9.PubMedGoogle Scholar
  15. 15.
    Pegoraro L, Abrahm J, Cooper RA, et al. Differentiation of human leukemias in response to 12-0-tetra-decanoylphorbol-13-acetata in vitro. Blood 1980; 55: 859–62.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • B. Löwenberg

There are no affiliations available

Personalised recommendations